To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors

NCT ID: NCT05388695

Last Updated: 2025-06-18

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-04-08
• Study Completion Date: 2027-05-30

Brief Summary

To observe the long-term efficacy and safety of dual-target chimeric antigen receptor T cells in the treatment of refractory relapsed B cell hematologic tumors (at least 2 years).

Detailed Description

This study is open single-arm prospective clinical study To relapse/refractory blood B cell tumor patients as the subjects, according to the expression of tumor cells, gives the corresponding double targets CART cell injection treatment, follow-up observation of the adverse reactions and the treatment effect of the drug to the data (at least 2 years), assessment of double targets CAR - T Long-term efficacy and safety of cell injection

Conditions

19 and 22+ B Cell Hematologic Tumors; 19 and 20+ B Cell Hematologic Tumors

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

19+22 CART and 19+20 CART

Eligible patients will be treated with 19+22 CAR-T and 19+20 CAR-T.

Group Type: EXPERIMENTAL

Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells

Intervention Type: BIOLOGICAL

Single or sequential injection of CD19, CD20 and CD22 CAR T cells.

Interventions

Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells

Single or sequential injection of CD19, CD20 and CD22 CAR T cells.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Refractory and relapsed B-cell tumor determined by clinical diagnosis, B cell tumors include the following three categories: B cell acute lymphocyte leucocyte; Inert B cell lymphoma (CLL、 FL、 MZL); Aggressive B-cell lymphoma (DLBCL、 BL、 MCL);

2. CD19 positive and CD20 positive or CD22 positive were detected by immunohistochemistry or flow cytometry; 3.18 years old≤age≤70 years old;

4.Estimated survival time>3 months; 5.ECOG Scores: 0~2; 6.There should be at least one measurable tumor foci according to RECIST Version 1.1; 7.The functions of vital organs must meet the following conditions: EF>50%, and no obvious abnormality of electrocardiogram; SpO2≥92%; Cr≤1.5ULN; ALTand AST≤5ULN, TBil≤3ULN; 8.Subjects planning to become pregnant must agree to use contraception prior to enrolling in the study and after six months of study duration; inform the investigator immediately if the subject becomes pregnant or suspects pregnancy; 9.The subject or guardian understands and signs the informed consent.

Exclusion Criteria

1. With other diseases that are not effectively controlled, including, but not limited to, persistent or poorly controlled infections symptomatic congestive heart failure unstable angina arrhythmia poorly controlled pulmonary disease or psychiatric disease;

2. Presence of other malignant tumors;

3. There are severe infections that cannot be effectively controlled;

4. Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive, peripheral blood hepatitis B virus (HBV)DNA higher than the detection limit should be excluded; If hepatitis C virus (HCV) antibody positive, peripheral blood HCV RNA positive need to exclude; Cytomegalovirus (CMV)DNA positive; Epstein-barr virus DNA positive in peripheral blood;

5. Known positive serology for human immunodeficiency virus (HIV) or syphilis;

6. A history of severe allergies to biological products (including antibiotics);

7. Patients with relapses after allogeneic hematopoietic stem cell transplantation with grade 3-4 acute graft-versus-host disease (GvHD);

8. Female patients who are under pregnancy and/or lactation;

9. Active autoimmune disease requiring systemic immunosuppressive therapy;

10. Conditions that the investigator believes may increase the risk to the subject or interfere with the results of the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hebei Taihe Chunyu Biotechnology Co., Ltd

INDUSTRY

Sponsor Role: collaborator

Hebei Senlang Biotechnology Inc., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jia Wei, PhD&MD

Role: PRINCIPAL_INVESTIGATOR

Tongji Hospital

Locations

Tongji Hospital

Wuhan, Hubei, China

Site Status: RECRUITING

Countries

China

Central Contacts

Jia Wei, PhD&MD

Role: CONTACT

jiawei@tjh.tjmu.edu.cn

008602783665555

Na Kuang, PhD&MD

Role: CONTACT

kuangna@senlangbio.com

008618630160116

Facility Contacts

Xiaoxi Zhou, PhD&MD

Role: primary

References

He S, Peng J, Yang X, Meng F, Huang L, Huang L, Tian W, Gao Z, Zhao J, Wang Z, Wei J. Peripheral Blood Smears Distinguish Infective Fever after CAR-T Therapy. Front Biosci (Landmark Ed). 2023 Nov 24;28(11):299. doi: 10.31083/j.fbl2811299.

Reference Type: DERIVED

PMID: 38062808 (View on PubMed)

Other Identifiers

19+22 for B-ALL/NHL

Identifier Type: -

Identifier Source: org_study_id